Search

everythinglearnresearchcommunity

for

Search:↓

Intralesional triamcinolone acetonide is effective for treating patchy hair loss, and dermoscopy helps detect treatment response and side effects early.

Monochromatic light devices, especially the 308-nm excimer laser, are promising for treating alopecia areata but more research is needed.

Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.

Patients with chronic graft-versus-host disease often have skin problems like vitiligo and alopecia areata.

Vitamin D levels are not linked to alopecia areata.

The AIRE gene variant rs2075876 is linked to a higher risk of alopecia areata in males.

Injecting platelet-rich plasma or applying it with a laser or microneedling can treat hair loss effectively. The laser and microneedling methods cause less pain.

Disrupted cysteine metabolism may cause hair breakage in Alopecia Areata, suggesting potential treatments like N-acetylcysteine.

The SARS-CoV-2 vaccine may be linked to triggering autoimmune conditions like Alopecia Areata.

Immunization and throat bacteria may increase the risk of a hair loss condition called alopecia areata.

Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

Traditional treatment for pediatric alopecia areata is most effective and should be first choice.

Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.

A woman's hair grew back after stopping acitretin for psoriasis and getting steroid treatment, and low vitamin D might be linked to alopecia severity.

0.05% Betamethasone Dipropionate is the most effective topical treatment for alopecia areata.

Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Low vitamin D levels may worsen or cause alopecia areata.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.

Alopecia areata patients often have undetected thyroid issues, so routine thyroid screening is recommended.

Both treatments are safe and effective, but anthralin may work better for some patients.

Alopecia areata might help slow down certain cancers.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

AA patients with comorbid conditions face more severe hair loss and need specific treatments.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

DPCP immunotherapy is effective for alopecia areata, and understanding influencing factors can improve treatment and satisfaction.

Adding PRP to topical mometasone improves and speeds up alopecia areata treatment.

Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.